Which has preferable earnings & valuation, IMUX or TIL?

Immunic is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunic N/A N/A -$97.17M -$5.58 N/A Instil Bio N/A N/A -$71.37M -$7.08 N/A

Is IMUX or TIL more profitable?

Instil Bio's return on equity of -39.76% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Immunic N/A -220.75% -132.04% Instil Bio N/A -39.76% -22.38%

Is KRRO or TIL more profitable?

Instil Bio has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. Instil Bio's return on equity of -39.76% beat Korro Bio's return on equity. Company Net Margins Return on Equity Return on Assets Korro Bio -1,834.48% -117.86% -71.04% Instil Bio N/A -39.76% -22.38%

Which has stronger earnings & valuation, TIL or NKTX?

Nkarta is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Instil Bio N/A N/A -$71.37M -$7.08 N/A Nkarta N/A N/A -$104.08M -$1.34 N/A

Is TIL or NKTX more profitable?

Nkarta's return on equity of -30.90% beat Instil Bio's return on equity. Company Net Margins Return on Equity Return on Assets Instil Bio N/A -39.76% -22.38% Nkarta N/A -30.90% -24.20%

Instil Bio (TIL) Competitors

$7.67 -0.02 (-0.23%)

As of 01:31 PM Eastern

Compare

TIL vs. KPTI, IMUX, KRRO, NKTX, and PRQR

Should you buy Instil Bio stock or one of its competitors? MarketBeat compares Instil Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Instil Bio include Karyopharm Therapeutics (KPTI), Immunic (IMUX), Korro Bio (KRRO), Nkarta (NKTX), and ProQR Therapeutics (PRQR). These companies are all part of the "pharmaceutical products" industry.

How does Instil Bio compare to Karyopharm Therapeutics?

Karyopharm Therapeutics (NASDAQ:KPTI) and Instil Bio (NASDAQ:TIL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.

In the previous week, Karyopharm Therapeutics had 1 more articles in the media than Instil Bio. MarketBeat recorded 2 mentions for Karyopharm Therapeutics and 1 mentions for Instil Bio. Instil Bio's average media sentiment score of 1.87 beat Karyopharm Therapeutics' score of 0.94 indicating that Instil Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Karyopharm Therapeutics	Positive
Instil Bio	Very Positive

Karyopharm Therapeutics presently has a consensus price target of $17.17, suggesting a potential upside of 80.40%. Instil Bio has a consensus price target of $66.00, suggesting a potential upside of 760.27%. Given Instil Bio's higher possible upside, analysts plainly believe Instil Bio is more favorable than Karyopharm Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Karyopharm Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Instil Bio has lower revenue, but higher earnings than Karyopharm Therapeutics. Instil Bio is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Karyopharm Therapeutics	$146.07M	1.48	-$196.04M	-$15.09	N/A
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A

Karyopharm Therapeutics has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Instil Bio has a beta of 1.91, meaning that its share price is 91% more volatile than the broader market.

66.4% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, 60.6% of Instil Bio shares are owned by institutional investors. 1.7% of Karyopharm Therapeutics shares are owned by insiders. Comparatively, 47.0% of Instil Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Instil Bio has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%. Karyopharm Therapeutics' return on equity of 0.00% beat Instil Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Karyopharm Therapeutics	-129.02%	N/A	-120.29%
Instil Bio	N/A	-39.76%	-22.38%

Summary

Karyopharm Therapeutics and Instil Bio tied by winning 8 of the 16 factors compared between the two stocks.

How does Instil Bio compare to Immunic?

Immunic (NASDAQ:IMUX) and Instil Bio (NASDAQ:TIL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

Instil Bio's return on equity of -39.76% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-220.75%	-132.04%
Instil Bio	N/A	-39.76%	-22.38%

Immunic currently has a consensus price target of $47.57, indicating a potential upside of 215.59%. Instil Bio has a consensus price target of $66.00, indicating a potential upside of 760.27%. Given Instil Bio's higher probable upside, analysts clearly believe Instil Bio is more favorable than Immunic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Immunic is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A

In the previous week, Immunic had 3 more articles in the media than Instil Bio. MarketBeat recorded 4 mentions for Immunic and 1 mentions for Instil Bio. Instil Bio's average media sentiment score of 1.87 beat Immunic's score of 0.73 indicating that Instil Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Immunic	Positive
Instil Bio	Very Positive

51.8% of Immunic shares are owned by institutional investors. Comparatively, 60.6% of Instil Bio shares are owned by institutional investors. 5.5% of Immunic shares are owned by insiders. Comparatively, 47.0% of Instil Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Immunic has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market. Comparatively, Instil Bio has a beta of 1.91, suggesting that its stock price is 91% more volatile than the broader market.

Summary

Instil Bio beats Immunic on 9 of the 14 factors compared between the two stocks.

How does Instil Bio compare to Korro Bio?

Korro Bio (NASDAQ:KRRO) and Instil Bio (NASDAQ:TIL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.

Instil Bio has lower revenue, but higher earnings than Korro Bio. Korro Bio is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Korro Bio	$6.39M	30.72	-$117.26M	-$11.67	N/A
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A

In the previous week, Korro Bio had 7 more articles in the media than Instil Bio. MarketBeat recorded 8 mentions for Korro Bio and 1 mentions for Instil Bio. Instil Bio's average media sentiment score of 1.87 beat Korro Bio's score of -0.12 indicating that Instil Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Korro Bio	Neutral
Instil Bio	Very Positive

13.2% of Korro Bio shares are owned by institutional investors. Comparatively, 60.6% of Instil Bio shares are owned by institutional investors. 4.8% of Korro Bio shares are owned by company insiders. Comparatively, 47.0% of Instil Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Korro Bio presently has a consensus target price of $16.71, indicating a potential upside of 22.76%. Instil Bio has a consensus target price of $66.00, indicating a potential upside of 760.27%. Given Instil Bio's higher possible upside, analysts plainly believe Instil Bio is more favorable than Korro Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Korro Bio has a beta of 3, suggesting that its share price is 200% more volatile than the broader market. Comparatively, Instil Bio has a beta of 1.91, suggesting that its share price is 91% more volatile than the broader market.

Instil Bio has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. Instil Bio's return on equity of -39.76% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Korro Bio	-1,834.48%	-117.86%	-71.04%
Instil Bio	N/A	-39.76%	-22.38%

Summary

Instil Bio beats Korro Bio on 10 of the 16 factors compared between the two stocks.

How does Instil Bio compare to Nkarta?

Instil Bio (NASDAQ:TIL) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

Instil Bio presently has a consensus target price of $66.00, indicating a potential upside of 760.27%. Nkarta has a consensus target price of $10.75, indicating a potential upside of 274.04%. Given Instil Bio's higher probable upside, equities analysts clearly believe Instil Bio is more favorable than Nkarta.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Nkarta	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

60.6% of Instil Bio shares are owned by institutional investors. Comparatively, 80.5% of Nkarta shares are owned by institutional investors. 47.0% of Instil Bio shares are owned by insiders. Comparatively, 9.8% of Nkarta shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Nkarta is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A

Nkarta's return on equity of -30.90% beat Instil Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-39.76%	-22.38%
Nkarta	N/A	-30.90%	-24.20%

In the previous week, Nkarta had 1 more articles in the media than Instil Bio. MarketBeat recorded 2 mentions for Nkarta and 1 mentions for Instil Bio. Instil Bio's average media sentiment score of 1.87 beat Nkarta's score of 0.94 indicating that Instil Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Instil Bio	Very Positive
Nkarta	Positive

Instil Bio has a beta of 1.91, indicating that its share price is 91% more volatile than the broader market. Comparatively, Nkarta has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market.

Summary

Instil Bio and Nkarta tied by winning 7 of the 14 factors compared between the two stocks.

How does Instil Bio compare to ProQR Therapeutics?

Instil Bio (NASDAQ:TIL) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

ProQR Therapeutics has higher revenue and earnings than Instil Bio. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A
ProQR Therapeutics	$17.99M	10.45	-$47.73M	-$0.50	N/A

Instil Bio has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -331.33%. Instil Bio's return on equity of -39.76% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-39.76%	-22.38%
ProQR Therapeutics	-331.33%	-84.87%	-37.78%

In the previous week, ProQR Therapeutics had 7 more articles in the media than Instil Bio. MarketBeat recorded 8 mentions for ProQR Therapeutics and 1 mentions for Instil Bio. Instil Bio's average media sentiment score of 1.87 beat ProQR Therapeutics' score of 0.50 indicating that Instil Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Instil Bio	Very Positive
ProQR Therapeutics	Positive

Instil Bio presently has a consensus price target of $66.00, indicating a potential upside of 760.27%. ProQR Therapeutics has a consensus price target of $7.33, indicating a potential upside of 310.83%. Given Instil Bio's higher possible upside, equities analysts clearly believe Instil Bio is more favorable than ProQR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Instil Bio has a beta of 1.91, suggesting that its stock price is 91% more volatile than the broader market. Comparatively, ProQR Therapeutics has a beta of 0.07, suggesting that its stock price is 93% less volatile than the broader market.

60.6% of Instil Bio shares are held by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are held by institutional investors. 47.0% of Instil Bio shares are held by company insiders. Comparatively, 8.4% of ProQR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Instil Bio beats ProQR Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Instil Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TIL vs. The Competition

Export

Metric	Instil Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$52.02M	$3.65B	$6.79B	$12.57B
Dividend Yield	N/A	2.20%	2.66%	6.16%
P/E Ratio	-1.08	21.44	27.46	25.42
Price / Sales	N/A	343.75	540.28	103.41
Price / Cash	N/A	143.77	48.53	58.59
Price / Book	0.46	8.67	10.94	6.65
Net Income	-$71.37M	$23.87M	$3.57B	$336.83M
7 Day Performance	0.42%	3.58%	2.71%	3.02%
1 Month Performance	-5.40%	3.61%	1.82%	0.62%
1 Year Performance	-65.02%	67.03%	36.26%	30.39%

Instil Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TIL Instil Bio	1.9502 of 5 stars	$7.67 -0.2%	$66.00 +760.3%	-63.1%	$52.02M	N/A	N/A	410	Positive News Gap Up
KPTI Karyopharm Therapeutics	2.2736 of 5 stars	$9.65 +7.2%	$17.17 +77.9%	+126.7%	$203.97M	$146.07M	N/A	380	High Trading Volume
IMUX Immunic	3.6444 of 5 stars	$15.07 +2.2%	$47.57 +215.7%	+120.4%	$200.92M	N/A	N/A	70	News Coverage
KRRO Korro Bio	2.3159 of 5 stars	$13.71 -1.4%	$16.71 +21.9%	+5.5%	$200.47M	$6.39M	N/A	70	High Trading Volume
NKTX Nkarta	4.0328 of 5 stars	$3.03 +8.6%	$10.75 +254.8%	+70.5%	$199.61M	N/A	N/A	140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TIL) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Instil Bio (TIL) Competitors

TIL vs. KPTI, IMUX, KRRO, NKTX, and PRQR

How does Instil Bio compare to Karyopharm Therapeutics?

Summary

How does Instil Bio compare to Immunic?

Summary

How does Instil Bio compare to Korro Bio?

Summary

How does Instil Bio compare to Nkarta?

Summary

How does Instil Bio compare to ProQR Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TIL vs. The Competition

Instil Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Instil Bio (TIL) Competitors

TIL vs. KPTI, IMUX, KRRO, NKTX, and PRQR

How does Instil Bio compare to Karyopharm Therapeutics?

Does the media prefer KPTI or TIL?

Do analysts rate KPTI or TIL?

Which has stronger earnings and valuation, KPTI or TIL?

Which has more volatility and risk, KPTI or TIL?

Do institutionals & insiders hold more shares of KPTI or TIL?

Is KPTI or TIL more profitable?

Summary

How does Instil Bio compare to Immunic?

Is IMUX or TIL more profitable?

Do analysts recommend IMUX or TIL?

Which has preferable earnings & valuation, IMUX or TIL?

Does the media refer more to IMUX or TIL?

Do institutionals and insiders believe in IMUX or TIL?

Which has more risk & volatility, IMUX or TIL?

Summary

How does Instil Bio compare to Korro Bio?

Which has stronger valuation & earnings, KRRO or TIL?

Does the media refer more to KRRO or TIL?

Do institutionals & insiders believe in KRRO or TIL?

Do analysts recommend KRRO or TIL?

Which has more risk and volatility, KRRO or TIL?

Is KRRO or TIL more profitable?

Summary

How does Instil Bio compare to Nkarta?

Do analysts recommend TIL or NKTX?

Do institutionals and insiders have more ownership in TIL or NKTX?

Which has stronger earnings & valuation, TIL or NKTX?

Is TIL or NKTX more profitable?

Does the media favor TIL or NKTX?

Which has more risk & volatility, TIL or NKTX?

Summary

How does Instil Bio compare to ProQR Therapeutics?

Which has stronger valuation and earnings, TIL or PRQR?

Is TIL or PRQR more profitable?

Does the media favor TIL or PRQR?

Do analysts rate TIL or PRQR?

Which has more volatility and risk, TIL or PRQR?

Do institutionals & insiders have more ownership in TIL or PRQR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TIL vs. The Competition

Instil Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools